Welcome to our dedicated page for Olema Pharmaceuticals news (Ticker: OLMA), a resource for investors and traders seeking the latest updates and insights on Olema Pharmaceuticals stock.
Olema Pharmaceuticals, Inc. (OLMA) is a clinical-stage biopharmaceutical company advancing targeted therapies for endocrine-driven breast cancers. This page provides investors and healthcare professionals with timely updates on clinical developments, financial disclosures, and strategic initiatives.
Access consolidated information about OLMA's lead candidate palazestrant (OP-1250), an oral complete estrogen receptor antagonist/SERD, and other pipeline assets like the KAT6 inhibitor OP-3136. Track regulatory milestones, partnership announcements, and peer-reviewed research findings in one centralized location.
Key updates include clinical trial progress, scientific conference presentations, and financial results. All content is sourced from official company communications and verified industry reports to ensure accuracy.
Bookmark this page for streamlined access to OLMA's latest developments in women's oncology therapeutics. Check regularly for essential updates impacting treatment innovation and corporate strategy.
Olema Oncology has announced two major developments: a clinical trial collaboration with Novartis and a $250 million private placement. The Novartis agreement will provide ribociclib drug supply for the planned Phase 3 OPERA-02 trial in frontline ER+/HER2- metastatic breast cancer, expected to start mid-2025. The private placement involves issuing shares at $9.08 and pre-funded warrants, with participation from notable investors including Adage Capital Partners, Bain Capital Life Sciences, and others. The funding will support OPERA-02, the ongoing Phase 3 OPERA-01 trial (with top-line data expected in 2026), and Phase 1/2 study of OP-3136.
Olema Oncology (Nasdaq: OLMA) announced it will present new data from its Phase 1b/2 clinical study at the San Antonio Breast Cancer Symposium (SABCS 2024). The study focuses on palazestrant (OP-1250) combined with CDK4/6 inhibitor ribociclib for treating ER+/HER2- advanced or metastatic breast cancer.
The poster presentation (ID: P2-09-16) is scheduled for December 11, 2024, from 5:30 to 7:00 p.m. CT in Halls 2-3. Olema will host an investor conference call on December 10, 2024, at 8:00 a.m. ET to discuss the findings. The poster will be available on Olema's website following the symposium's embargo policy.
Olema Oncology (OLMA) reported Q3 2024 financial results with a cash position of $214.8 million as of September 30, 2024. The company recorded a net loss of $34.6 million, up from $21.5 million in Q3 2023, primarily due to increased R&D expenses of $33.2 million. The company presented new preclinical data for OP-3136, their KAT6 inhibitor, and continues enrollment in the OPERA-01 Phase 3 trial of palazestrant. Olema plans to submit an IND application for OP-3136 before year-end and initiate Phase 1 trials in early 2025.
Olema Oncology (Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer, has announced its participation in three upcoming investor conferences. The company will attend the Jefferies London Healthcare Conference on November 20, 2024, at 1:30 p.m. GMT, the Evercore HealthCONx Conference on December 3, 2024, at 2:10 p.m. ET, and Citi's Global Healthcare Conference on December 3, 2024, at 3:15 p.m. ET. The events will feature various presentation formats including fireside chats and panel discussions. Live webcasts will be available on Olema's investor relations website and archived for at least 30 days.
Olema Pharmaceuticals (Nasdaq: OLMA) has granted stock options to one new employee as part of its inducement program. The grant includes options to purchase 2,500 shares of common stock at an exercise price of $11.62 per share. The options vest over four years, with 25% vesting after the first year and the remainder vesting monthly over three years. The options have a 10-year term and were granted under the company's 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Olema Oncology presented preclinical data at ENA 2024 showcasing anti-tumor activity of their drug candidates. OP-3136, a KAT6 inhibitor, demonstrated strong anti-tumor activity alone and enhanced effects when combined with palazestrant. The company plans to submit an IND application for OP-3136 by year-end. Additionally, palazestrant showed improved tumor suppression when combined with everolimus and capivasertib in ER+/HER2- breast cancer models. The studies revealed synergistic effects and significant tumor regression, particularly when palazestrant was combined with these agents, showing superior results compared to fulvestrant combinations.
Olema Oncology (Nasdaq: OLMA) announced upcoming poster presentations at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024) in Barcelona, Spain, from October 23-25, 2024. The presentations will showcase new preclinical data on combination therapies for ER+/HER2- breast cancer.
Three posters will be presented on October 24, 2024:
- Combining palazestrant (CERAN) with everolimus (mTOR inhibitor)
- Combining palazestrant with capivasertib (pan-AKT inhibitor)
- Combining OP-3136 (KAT6 inhibitor) with endocrine therapy and CDK4/6 inhibitor
These studies demonstrate enhanced tumor suppression and anti-tumor activity in ER+/HER2- breast cancer models. Abstracts and posters will be available on the ENA website and Olema's website, respectively.
Olema Pharmaceuticals, a clinical-stage biopharmaceutical company focused on targeted therapies for women's cancers, has announced the granting of stock options to three new employees. These options allow the purchase of 118,800 shares of the company's common stock, effective October 1, 2024. The grants were approved by the Compensation Committee and issued under Olema's 2022 Inducement Plan, in compliance with Nasdaq Listing Rule 5635(c)(4).
The stock options have a 10-year term and an exercise price of $12.30 per share, matching the last reported sale price on October 1, 2024. They vest over four years, with 25% vesting on the first anniversary and the remainder in 36 equal monthly installments, subject to continuous employment. This announcement is made in accordance with Nasdaq Listing Rule 5635(c)(4).
Olema Pharmaceuticals (Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on targeted therapies for women's cancers, has granted stock options to five new employees. The options allow the purchase of 130,600 shares of common stock at an exercise price of $11.35 per share, equal to the last reported sale price on September 3, 2024. These inducement grants, approved under Nasdaq Listing Rule 5635(c)(4), vest over four years with a 10-year term. The options were granted under Olema's 2022 Inducement Plan as part of the company's employee retention and attraction strategy.
Olema Oncology (Nasdaq: OLMA), a clinical-stage biopharmaceutical company specializing in targeted therapies for women's cancers, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The event is scheduled for Wednesday, September 4, 2024, at 7:45 a.m. ET at the Marriott Marquis in New York, NY.
The company's management team will engage in a Fireside Chat format discussion. Investors and interested parties can access a live webcast of the chat through the News & Events section of Olema's investor relations website at ir.olema.com. The webcast will remain archived for at least 30 days after the event, providing an opportunity for those unable to attend live to catch up on the discussion.
FAQ
What is the current stock price of Olema Pharmaceuticals (OLMA)?
What is the market cap of Olema Pharmaceuticals (OLMA)?
